Title
Category
Credits
Event date
Cost
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The treatment landscape for relapsed/refractory Hodgkin lymphoma has changed significantly in recent years with the incorporation of novel agents such as brentuximab vedotin and the checkpoint inhibitors nivolumab or pembrolizumab. Second-line and subsequent therapy decisions are complex and must take into account multiple factors, such as use of novel agents in the frontline setting and the potential unique toxicities of novel agents.
Updates to Management of Multiple Myeloma
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Best Practices for Oncology Urgent Care
  • Supportive Care Topics
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Oncology urgent care is an emerging area of interest requiring many clinical and practical considerations for implementation. Education is needed on the value of offering oncology urgent care and the factors that lead to successful programs.
Updates in the Multidisciplinary Approach for Resectable Gastroesophageal Adenocarcinoma and Peritoneal-Limited Disease
  • Gastric/Esophageal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for gastroesophageal tumors is expanding, including the role of systemic therapy plus surgery. It is essential for healthcare professionals (HCPs) in community and academic settings to be aware of and understand current and emerging treatment options and associated evidence, even that which is limited and may be controversial.
Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors
  • Neuroendocrine Tumors
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As there are no data to support a specific sequence of regional versus systemic therapy or to guide sequencing of systemic therapy options, it is important for physicians to be aware of the available treatment options and emerging data on novel therapies so they can provide individualized care for their patients.
Updates to the Management of Cervical Cancer
  • Cervical Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The systemic therapy section of the NCCN Guidelines for Cervical Cancer has continuously added new IO therapy options over the past few years to reflect the new approvals. Knowledge in this topic will guide the practitioners in appropriately prioritizing these new treatment options to further improve patient outcomes. 
Updates to Systemic Therapy for Differentiated Thyroid Cancer
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Managing differentiated thyroid carcinoma (DTC) can be a challenge, because until recently, few prospective randomized trials of treatment have been done. Most of the information about treatment comes from studies of large cohorts of patients for whom therapy has not been randomly assigned. Targeted therapy for DTC is an active area of investigation.
Plenary Session: Addressing Mental Health in Cancer Care: Optimizing Interdisciplinary Psychosocial Support
  • Distress Management
  • Supportive Care Topics
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
$0.00
The early recognition and management of concerns related to mental health and well-being are vitally important for maintaining quality of life, health, and safety of patients with cancer and cancer survivors.
Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
05/21/2025
$0.00
Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.  Pharmacists can play a role in appropriate treatment selection, monitoring, and modification.
NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
05/22/2025
$0.00
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.

Pages